Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols.
We have examined whether inhibitors of angiotensin-converting enzyme-containing sulfhydryl groups such as, captopril (CPT) or SQ 14,534, the nonsulfhydryl-containing angiotensin-converting enzyme inhibitors, teprotide (TPR) or enalaprilat (ENA) and other structurally unrelated sulfhydryl-containing compounds, N-2-mercaptopropionylglycine (MPG) or N-acetyl-L-cysteine (NAC), could influence platelet aggregation. Incubation of human washed platelets with CPT, SQ 14,534, TPR, ENA, MPG or NAC (0.1-0.5 mM) did not modify their aggregatory responses to thrombin. However, the antiaggregatory properties of endothelial cells cultured from bovine aorta were potentiated by CPT, SQ 14,534, MPG or NAC but not by TPR or ENA (40-100 microM). CPT (100-500 microM) or NAC (50-200 microM) but not ENA (100 and 500 microM) also potentiated the antiaggregatory effects of sodium nitroprusside (1.0 microM) or iloprost (0.2 nM). The ability of the thiol-containing compounds (CPT or NAC) to potentiate the antiaggregatory effects of sodium nitroprusside or iloprost was not associated with an elevation of platelet cyclic GMP or cyclic AMP levels, respectively. Thus, CPT and other sulfhydryl-containing compounds can synergize with antiplatelet compounds, thereby enhancing the ability of endothelial-derived autocoids to inhibit platelet aggregation. The mechanism responsible for this potentiating effect of thiols on platelet aggregation is not known, but may relate to the ability of thiol-containing compounds to act as intracellular scavengers of oxygen-derived free radicals.
Mollace
V
V
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, United Kingdom.
Salvemini
D
D
Sessa
W C
WC
Vane
J R
JR
D000111:Acetylcysteine / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002216:Captopril / Q000494:pharmacology*; D004357:Drug Synergism; D015773:Enalaprilat / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology; D006801:Humans; D016285:Iloprost / Q000494:pharmacology*; D009569:Nitric Oxide / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology*; D009712:Nucleotides, Cyclic / Q000097:blood; D010975:Platelet Aggregation Inhibitors; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D013722:Teprotide / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology
D009712:Nucleotides, Cyclic; D010975:Platelet Aggregation Inhibitors; D013438:Sulfhydryl Compounds; D009599:Nitroprusside; D009569:Nitric Oxide; D002216:Captopril; D013722:Teprotide; D013917:Thrombin; D015773:Enalaprilat; D016285:Iloprost; D000111:Acetylcysteine